L Ossowski

Summary

Affiliation: Mount Sinai School of Medicine
Country: USA

Publications

  1. pmc Computer aided identification of small molecules disrupting uPAR/alpha5beta1--integrin interaction: a new paradigm for metastasis prevention
    Pratima Chaurasia
    Division of Hematology Oncology, Department of Medicine, Mount Sinai School of Medicine, New York, New York, USA
    PLoS ONE 4:e4617. 2009
  2. pmc RARα1 control of mammary gland ductal morphogenesis and wnt1-tumorigenesis
    Ellen Cohn
    Division of Hematology Oncology, Tisch Cancer Institute, Mount Sinai School of Medicine, New York, NY 10029, USA
    Breast Cancer Res 12:R79. 2010
  3. ncbi request reprint Urokinase receptor and integrin partnership: coordination of signaling for cell adhesion, migration and growth
    L Ossowski
    Rochelle Belfer Chemotherapy Foundation, Division of Medical Oncology, Department of Medicine, Box 1178, Mount Sinai School of Medicine, New York, New York 11029, USA
    Curr Opin Cell Biol 12:613-20. 2000
  4. pmc Dormancy of metastatic melanoma
    Liliana Ossowski
    Division of Hematology and Oncology, Department of Medicine, Mount Sinai School of Medicine, New York, NY, USA
    Pigment Cell Melanoma Res 23:41-56. 2010
  5. pmc Tumor dormancy induced by downregulation of urokinase receptor in human carcinoma involves integrin and MAPK signaling
    J A Aguirre Ghiso
    Rochelle Belfer Chemotherapy Foundation Laboratory, Division of Medical Oncology, Department of Medicine, Mount Sinai School of Medicine, New York, NY 10029, USA
    J Cell Biol 147:89-104. 1999
  6. ncbi request reprint The role of plasminogen activator receptor in cancer invasion and dormancy
    L Ossowski
    Department of Medicine, Mount Sinai School of Medicine, New York, NY, USA
    Medicina (B Aires) 59:547-52. 1999
  7. pmc Urokinase receptor and fibronectin regulate the ERK(MAPK) to p38(MAPK) activity ratios that determine carcinoma cell proliferation or dormancy in vivo
    J A Aguirre-Ghiso
    Rochelle Belfer Chemotherapy Foundation Laboratory, Division of Medical Oncology, Department of Medicine, Mount Sinai School of Medicine, New York, New York 10029, USA
    Mol Biol Cell 12:863-79. 2001

Research Grants

Collaborators

Detail Information

Publications7

  1. pmc Computer aided identification of small molecules disrupting uPAR/alpha5beta1--integrin interaction: a new paradigm for metastasis prevention
    Pratima Chaurasia
    Division of Hematology Oncology, Department of Medicine, Mount Sinai School of Medicine, New York, New York, USA
    PLoS ONE 4:e4617. 2009
    ..We also identified the site on uPAR that binds alpha5beta1-integrin. Disruption of uPAR/integrin interaction blocks ERK activation and forces cancer cells into dormancy...
  2. pmc RARα1 control of mammary gland ductal morphogenesis and wnt1-tumorigenesis
    Ellen Cohn
    Division of Hematology Oncology, Tisch Cancer Institute, Mount Sinai School of Medicine, New York, NY 10029, USA
    Breast Cancer Res 12:R79. 2010
    ..We tested a single receptor isotype, RARα1, for its role in mouse mammary gland morphogenesis and MMTV-wnt1-induced oncogenesis...
  3. ncbi request reprint Urokinase receptor and integrin partnership: coordination of signaling for cell adhesion, migration and growth
    L Ossowski
    Rochelle Belfer Chemotherapy Foundation, Division of Medical Oncology, Department of Medicine, Box 1178, Mount Sinai School of Medicine, New York, New York 11029, USA
    Curr Opin Cell Biol 12:613-20. 2000
    ....
  4. pmc Dormancy of metastatic melanoma
    Liliana Ossowski
    Division of Hematology and Oncology, Department of Medicine, Mount Sinai School of Medicine, New York, NY, USA
    Pigment Cell Melanoma Res 23:41-56. 2010
    ..Ultimately, understanding the biology of dormancy and the mechanisms of dormant cell survival, might allow for their specific targeting and elimination...
  5. pmc Tumor dormancy induced by downregulation of urokinase receptor in human carcinoma involves integrin and MAPK signaling
    J A Aguirre Ghiso
    Rochelle Belfer Chemotherapy Foundation Laboratory, Division of Medical Oncology, Department of Medicine, Mount Sinai School of Medicine, New York, NY 10029, USA
    J Cell Biol 147:89-104. 1999
    ....
  6. ncbi request reprint The role of plasminogen activator receptor in cancer invasion and dormancy
    L Ossowski
    Department of Medicine, Mount Sinai School of Medicine, New York, NY, USA
    Medicina (B Aires) 59:547-52. 1999
    ..We show that very high levels of active ERK are required to keep cancer cells proliferating in vivo...
  7. pmc Urokinase receptor and fibronectin regulate the ERK(MAPK) to p38(MAPK) activity ratios that determine carcinoma cell proliferation or dormancy in vivo
    J A Aguirre-Ghiso
    Rochelle Belfer Chemotherapy Foundation Laboratory, Division of Medical Oncology, Department of Medicine, Mount Sinai School of Medicine, New York, New York 10029, USA
    Mol Biol Cell 12:863-79. 2001
    ..Together these results indicate that uPAR and its interaction with the integrin should be considered important targets for induction of tumor dormancy...

Research Grants12

  1. FACTORS INVOLVED IN MALIGNANT BEHAVIOR OF HUMAN TUMORS
    Liliana Ossowski; Fiscal Year: 2007
    ....
  2. ABERRANT RETINOID SIGNALING IN BREAST CANCER
    Liliana Ossowski; Fiscal Year: 2007
    ..This has direct implications to future retinoid clinical trials in that it advocates that participating patients be carefully stratified based on the molecular characteristics of their cancer. ..
  3. FACTORS INVOLVED IN MALIGNANT BEHAVIOR OF HUMAN TUMORS
    Liliana Ossowski; Fiscal Year: 2006
    ....
  4. FACTORS INVOLVED IN MALIGNANT BEHAVIOR OF HUMAN TUMORS
    Liliana Ossowski; Fiscal Year: 2005
    ....
  5. FACTORS INVOLVED IN MALIGNANT BEHAVIOR OF HUMAN TUMORS
    Liliana Ossowski; Fiscal Year: 2004
    ....
  6. FACTORS INVOLVED IN MALIGNANT BEHAVIOR OF HUMAN TUMORS
    Liliana Ossowski; Fiscal Year: 2003
    ....
  7. FACTORS INVOLVED IN MALIGNANT BEHAVIOR OF HUMAN TUMORS
    Liliana Ossowski; Fiscal Year: 2002
    ..The initial experiments will be performed in chick embryos, and whenever possible or necessary, confirmed in nude mice. ..
  8. FACTORS INVOLVED IN MALIGNANT BEHAVIOR OF HUMAN TUMORS
    Liliana Ossowski; Fiscal Year: 2001
    ..The initial experiments will be performed in chick embryos, and whenever possible or necessary, confirmed in nude mice. ..
  9. FACTORS INVOLVED IN MALIGNANT BEHAVIOR OF HUMAN TUMORS
    Liliana Ossowski; Fiscal Year: 2000
    ..The initial experiments will be performed in chick embryos, and whenever possible or necessary, confirmed in nude mice. ..
  10. FACTORS INVOLVED IN MALIGNANT BEHAVIOR OF HUMAN TUMORS
    Liliana Ossowski; Fiscal Year: 1999
    ..The initial experiments will be performed in chick embryos, and whenever possible or necessary, confirmed in nude mice. ..